Georgia GLP-1 Weight Loss Compliance 2026: Semaglutide, Tirzepatide & GA Prescribing Rules

Two federal dates ended the compounded GLP-1 boom that built half the weight-loss programs in Georgia med spas: October 2024, when the FDA removed tirzepatide from its drug shortage list, and February 21, 2025, when semaglutide came off as well.

Once a drug is off the shortage list, the federal "essentially-a-copy" rule kicks back in. Section 503A of the Food, Drug, and Cosmetic Act prohibits a state-licensed compounding pharmacy from compounding a drug that is essentially a copy of a commercially available FDA-approved product, except in narrow clinical circumstances. The shortage was the loophole. The shortage is gone.

For Georgia med spas, that change layers onto a state regulatory environment with two active enforcement bodies: the Georgia Composite Medical Board (GCMB), which licenses physicians and PAs and writes the rules on telemedicine and good-faith examinations, and the Georgia Drugs and Narcotics Agency (GDNA), which inspects pharmacies, monitors the PDMP, and refers cases to the Board of Pharmacy. Both have signaled that high-volume online weight-loss prescribing without a real clinical encounter is on their radar.

This guide covers what Georgia med spas can actually do in 2026 — what to prescribe, how to document it, where telehealth fits, and the GCMB patterns to avoid.

What Changed: The End of the Compounded GLP-1 Era

From roughly 2022 through mid-2024, FDA-approved GLP-1s were on the federal drug shortage list. That status had a specific consequence: compounding pharmacies could legally produce copies of semaglutide and tirzepatide for individual patients. Med spas across Georgia — especially in metro Atlanta, Savannah, and Augusta — built entire programs on this, sourcing compounded vials at $200–$400/month versus $900–$1,300/month retail for the branded products.

Tirzepatide — Off the List October 2024

The FDA declared the tirzepatide shortage resolved in October 2024 after Eli Lilly confirmed that supply of Mounjaro and Zepbound had stabilized. After a brief court-extended transition window, both 503A pharmacies and 503B outsourcing facilities lost the routine ability to compound tirzepatide copies.

Semaglutide — Off the List February 21, 2025

Novo Nordisk reached supply normalization later. The FDA removed semaglutide from the shortage list on February 21, 2025. The transition for compounded semaglutide effectively ended in spring 2025, with the same outcome: 503A compounding of copies is no longer broadly permitted.

The current FDA shortage status for any GLP-1 should be verified directly at the FDA Drug Shortages database before relying on a compounding-based protocol.

What's Still Allowed

Compounding hasn't disappeared entirely. Narrow paths remain:

• Documented clinical difference: A compounded formulation that is not "essentially a copy" — for example, a clinically necessary dose strength not available in the FDA-approved product, or an ingredient combination clinically indicated for a specific patient.
• Component allergy or intolerance: A documented patient-specific clinical need (such as an inactive-ingredient allergy) supported in the chart.
• 503B outsourcing facilities: Limited compounding under stricter FDA conditions, primarily for hospitals and clinics with documented need — not the routine commercial supply that fed med spa programs.

"My patient prefers the lower price" is not a clinical difference. "We always used compounded" is not a clinical difference. Those rationales will not survive a GCMB review or a GDNA pharmacy inspection.

What Georgia Med Spas Can Legally Prescribe in 2026

The Branded GLP-1 List

FDA-approved products that a Georgia-licensed prescriber can lawfully prescribe today:

• Semaglutide — Wegovy (weight loss indication), Ozempic (T2DM), Rybelsus (oral T2DM)
• Tirzepatide — Zepbound (weight loss), Mounjaro (T2DM)
• Liraglutide — Saxenda (weight loss), Victoza (T2DM)

Wegovy and Zepbound are the labeled-for-weight-loss options. Ozempic and Mounjaro are diabetes products that are sometimes prescribed off-label for weight management; off-label prescribing remains legal in Georgia when supported by a documented clinical rationale, but the chart must reflect that rationale.

Off-Label Prescribing in Georgia

Georgia does not prohibit off-label prescribing, but the standard of care still applies. If you prescribe Ozempic for a patient without diabetes, the chart needs to show why — BMI thresholds, comorbidities, prior weight-loss attempts, why a labeled product (Wegovy, Zepbound) wasn't used, and informed consent that addresses off-label use. Lack of this documentation is one of the most common findings in GCMB weight-loss cases.

Who Can Prescribe GLP-1s at a Georgia Med Spa

Georgia's prescribing-authority rules apply. The provider must be:

• A Georgia-licensed physician (MD or DO) in good standing with the GCMB, or
• A Georgia-licensed APRN (advanced practice registered nurse) prescribing under a written nurse protocol agreement with a Georgia-licensed delegating physician, or
• A Georgia-licensed physician assistant (PA) prescribing under a job description approved by the GCMB and supervised by a primary supervising physician

APRNs in Georgia do not have independent prescriptive authority. The nurse protocol agreement must explicitly include the categories of drugs the APRN may prescribe — weight-management/GLP-1s should be listed by category if the APRN will be writing those prescriptions. The delegating physician must be readily available and conduct chart reviews on the schedule specified in the protocol.

RNs cannot prescribe. They can administer GLP-1 injections under a valid order from a Georgia prescriber, but the prescribing decision — the good-faith examination, the medical necessity assessment, the chart entry — must come from a physician, APRN under protocol, or PA. For more on Georgia scope of practice, see the Georgia injection scope guide.

The "Good Faith Examination" — What Georgia Requires

Georgia's good-faith examination requirement is grounded in GCMB Rule 360-3-.02 (unprofessional conduct) and reinforced by GCMB Rule 360-32-.06, which sets the telemedicine standard of care. The examination must be sufficient to establish a diagnosis and a treatment plan — and it must be documented.

Minimum Elements Documented

1. Patient history — current medications, allergies, prior weight-loss attempts, relevant surgical history, family history
2. Anthropometrics — verified height, weight, and BMI (a self-reported value alone is not adequate when the patient could be reasonably weighed)
3. Comorbidities — Type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, prediabetes — these establish medical necessity
4. Contraindication screen — personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), pancreatitis, severe gastrointestinal disease, gastroparesis, pregnancy or pregnancy planning, severe renal or hepatic impairment
5. Mental health screen — eating disorder history, suicidality (FDA labeling for GLP-1s notes psychiatric considerations)
6. Informed consent — risks, benefits, common adverse events (nausea, vomiting, constipation), serious risks (pancreatitis, gallbladder disease, MTC warning), pregnancy considerations, off-label use if applicable
7. Treatment plan — starting dose, titration schedule, follow-up intervals, monitoring plan, criteria for dose change or discontinuation

Recommended Pre-Treatment Labs

Not statutorily required for every patient, but standard of care for a GLP-1 weight-loss program — and what GCMB reviewers look for in a defensible chart:

• Hemoglobin A1c
• Comprehensive metabolic panel (kidney and liver function)
• Lipid panel
• TSH (thyroid function)
• Lipase (baseline if pancreatitis history is present)
• Pregnancy test for patients of childbearing potential

Telehealth Prescribing of GLP-1s in Georgia

Georgia permits the establishment of a physician-patient relationship via telehealth under O.C.G.A. §43-34-31.1 and the implementing rule, GCMB Rule 360-32-.06. An in-person visit is not federally or state-required to issue a non-controlled prescription like a GLP-1.

However, telehealth does not lower the bar on the good-faith examination — it changes how the examination is conducted. The visit must still be a real clinical encounter, with synchronous audio-video where clinically appropriate.

Georgia Telehealth Requirements for GLP-1 Prescribing

• Synchronous interaction: Live audio-video for the initial visit. An online intake form alone is not sufficient under Rule 360-32-.06.
• Provider identity and licensure verification: The patient must be able to verify the prescriber's identity and Georgia license
• Patient location at time of service: The patient must be physically present in Georgia at the time of the encounter (or the provider must be licensed in the patient's state)
• Informed telehealth consent: Specific consent for telehealth — separate from medical informed consent — including discussion of telehealth limitations, privacy, and emergency procedures
• HIPAA-compliant platform: The video platform must support HIPAA, and patient records are subject to O.C.G.A. §31-33 medical records access rules
• Continuity and emergency plan: The chart must reflect a plan for in-person follow-up or referral if clinically indicated

The model that triggers GCMB complaints is the "5-minute intake" — a patient fills a web form, a clinician they never speak to issues a prescription, and a compounded vial ships from out of state. That model is not a good-faith examination, and the GCMB has issued discipline against physicians who structured their practice this way, regardless of how many patients were behind them.

Pharmacy Partnership Rules in Georgia: GDNA and the Board of Pharmacy

The dispensing pharmacy is your second compliance surface. Georgia has a distinctive two-agency structure: the Georgia State Board of Pharmacy licenses pharmacies and pharmacists, while the Georgia Drugs and Narcotics Agency conducts inspections, investigations, and enforcement on behalf of the Board. GDNA is the agency that walks into the pharmacy.

In-State Dispensing Pharmacies

A Georgia-licensed retail or specialty pharmacy can dispense Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda directly to your patient on a valid Georgia prescription. Most large chains (CVS, Walgreens, Publix, independents) and weight-loss-focused specialty pharmacies meet this standard.

Out-of-State / Mail-Order Pharmacies

An out-of-state pharmacy can ship to Georgia patients only if it holds a current non-resident pharmacy registration with the Georgia State Board of Pharmacy. Before partnering, verify the registration:

• Confirm the non-resident registration is active and in good standing on the Board's verification system
• Confirm the pharmacy carries the FDA-approved branded products and is not relying on compounded substitutions
• Get the registration number in writing for your file — GDNA can request it during an inspection

Compounding Pharmacy Red Flags

If a pharmacy currently offers your med spa "compounded semaglutide" or "compounded tirzepatide" without a documented patient-specific clinical rationale, walk away. The legal exposure is on the prescriber as well as the pharmacy. A GDNA inspection or a Board of Pharmacy referral can quickly become a GCMB complaint, and the prescription record will lead directly back to your chart.

Refills, Follow-Up, and Continued Prescribing

Georgia does not specify a fixed follow-up interval for weight-loss prescribing, but standard of care drives the schedule, and GCMB Rule 360-32-.06 requires ongoing care to be coordinated with the patient's medical home where appropriate:

• First follow-up: 4 weeks after initiation — assess tolerance, side effects, weight response, dose titration
• Subsequent follow-ups: Every 4–12 weeks during titration
• Maintenance: At least every 3 months once stable
• Annual labs: Repeat A1c, kidney/liver function, lipid panel
• Discontinuation criteria: Documented in the plan — stop if weight loss less than 5% at 12 weeks at maintenance dose, intolerable side effects, contraindication develops, or pregnancy

Auto-refilling a GLP-1 for 12+ months without a follow-up encounter is a structural GCMB red flag. Build a recall workflow before you write the first prescription.

GCMB Overprescribing Patterns in Georgia

The Georgia Composite Medical Board enforces medical practice misconduct under O.C.G.A. Title 43, Chapter 34. The patterns that have produced GLP-1-related discipline in Georgia mirror what's seen nationally — but with GCMB Rule 360-32-.06 giving the Board a direct telemedicine hook:

Pattern 1: Form-Driven Prescribing

The patient fills out a web form. A reviewing clinician checks boxes and signs off. There is no synchronous encounter. The chart is essentially the form. The GCMB has treated this as failure to conduct a good-faith examination under both 360-32-.06 and the broader unprofessional conduct rule.

Pattern 2: Weak or Missing Nurse Protocol

An APRN prescribing GLP-1s under a nurse protocol agreement that doesn't actually authorize weight-management drugs, or under an agreement with a delegating physician who has no real involvement. Georgia takes the protocol agreement seriously — the GCMB will pull it during an investigation and read it.

Pattern 3: Missing Contraindication Screening

Charts that do not document the MTC/MEN-2 family-history screen, pancreatitis screen, or pregnancy screen. The black-box warning on GLP-1 labeling exists for a reason; charts that ignore it are easy targets in a Board review.

Pattern 4: Missing Telehealth Consent

The chart contains a generic medical consent but no separate telehealth-specific consent. Georgia treats telehealth consent as a distinct disclosure obligation under Rule 360-32-.06.

Pattern 5: Advertising and Scope Mismatches

Marketing that promises GLP-1s "without the doctor visit" or implies anyone can get a prescription. Georgia's advertising rules prohibit misleading claims, and the GCMB increasingly cross-references advertising language against the actual clinical workflow during investigations.

How Georgia Compares to Federal GLP-1 Standards

Most of what Georgia requires also tracks federal best practice. For the federal-level picture and how it applies across states, see our national GLP-1 weight-loss compliance guide. Georgia-specific layers on top:

• GCMB Rule 360-32-.06 codifies the telemedicine standard of care, making the good-faith examination explicitly enforceable
• The non-resident pharmacy registration requirement is enforced, with GDNA as the inspection arm
• APRN prescribing requires a written nurse protocol agreement that explicitly covers weight-management drugs
• The GDNA + Board of Pharmacy + GCMB three-agency structure means a complaint at any one of them can cascade

The Operational Checklist

If you operate a Georgia med spa offering GLP-1s, this is the minimum operational stack you should be able to produce on demand:

1. Written GLP-1 SOP signed by the medical director, covering eligibility, contraindications, dose titration, monitoring, and discontinuation
2. Patient assessment template with all good-faith examination elements
3. Contraindication screening checklist (MTC/MEN-2, pancreatitis, pregnancy, gastroparesis, etc.)
4. Informed consent form covering risks, benefits, off-label use, pregnancy
5. Telehealth informed consent separate from medical consent, aligned with GCMB Rule 360-32-.06
6. HIPAA-compliant telehealth platform with synchronous audio-video
7. Pharmacy partnership documentation — copy of Georgia pharmacy license or non-resident registration
8. Follow-up workflow with scheduled recalls at 4 weeks, then 4–12 weeks during titration
9. Discontinuation criteria documented in the SOP
10. Adverse event log tracking nausea/GI events, suspected pancreatitis, gallbladder events
11. APRN nurse protocol agreement (if applicable) with weight-management explicitly included in the authorized drug categories

For the broader Georgia compliance picture across all procedures, see the Georgia med spa compliance checklist and the Georgia medical director requirements guide.

PDMP, EPCS, and Controlled Substances — What Doesn't Apply

For clarity: GLP-1 receptor agonists are not controlled substances. They are not subject to:

• Georgia PDMP reporting (administered through GDNA — applies only to Schedule II–V controlled substances)
• EPCS (Electronic Prescribing of Controlled Substances) mandates
• DEA registration for the prescriber (a DEA number is needed only if the practice prescribes any controlled substance)

Electronic prescribing for GLP-1s is best practice for legibility, audit, and pharmacy efficiency, but is not legally mandated under Georgia PDMP rules. If your practice also offers other weight-management drugs that are controlled (phentermine, for example, is a Schedule IV controlled substance), those are subject to Georgia PDMP queries and EPCS — and that's a separate workflow with separate GDNA oversight.

Summary

1. The FDA removed tirzepatide (October 2024) and semaglutide (February 2025) from its drug shortage list — routine 503A compounded GLP-1s are no longer broadly legal
2. Georgia med spas should prescribe FDA-approved branded GLP-1s: Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda
3. A "good faith examination" is required before prescribing under GCMB Rule 360-32-.06 — BMI, comorbidities, contraindications, informed consent, treatment plan
4. Telehealth prescribing is permitted under O.C.G.A. §43-34-31.1, but a synchronous audio-video encounter and separate telehealth consent are required
5. Out-of-state pharmacies must hold a Georgia non-resident pharmacy registration to ship into the state, and GDNA inspects them
6. The GCMB has disciplined providers for form-driven prescribing, missing contraindication screens, and weak nurse protocol agreements
7. GLP-1s are not controlled — not in the Georgia PDMP, not subject to EPCS — but documentation expectations are higher than for many non-controlled drugs

Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. GLP-1 prescribing involves federal and state regulatory considerations that change frequently. Verify current FDA shortage status and consult with a Georgia healthcare attorney and your medical director before establishing or modifying a weight-loss program.